Drug intelligence / Profile preview

ECwN + varenicline

Development stage
Phase 4
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

ECwN + varenicline appears to be a combination treatment used for smoking cessation. It includes varenicline (previously marketed as Chantix) and likely a nicotine replacement therapy (NRT) component represented by "ECwN". Varenicline is a prescription medication that aids smoking cessation by acting as a partial agonist at nicotinic acetylcholine receptors (nAChRs) in the brain. It stimulates these receptors at a lower level than nicotine, thereby reducing cravings and withdrawal symptoms, while also blocking nicotine from binding. Clinical trials mentioned in the search results suggest that combining varenicline with nicotine patches can improve efficacy for smoking cessation compared to varenicline alone, particularly in specific groups like male smokers, highly dependent smokers, and heavy drinkers. The combination appears generally well-tolerated according to trial data, although it may result in more side effects than varenicline used alone. Potential side effects reported include nausea, vomiting, headache, dizziness, upset stomach, and tiredness.

02

Targets

α3α5β4 nAChR (α3α5β4 nicotinic receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)α6β2 nAChR (α6β2 nicotinic receptor)CHRNA7 (α7 nicotinic receptor)

Beyond the preview

Go deeper on ECwN + varenicline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECwN + varenicline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call